Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708175 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.
A Phase 4 study of Bone Metabolism, sponsored by Takeda.
- Completed
- Registry status
- Phase 4
- Development phase
- 156
- Enrollment target
- 20
- Study locations
NCT00708175 is a Phase 4 study of Bone Metabolism that has completed, run by Takeda. The registered enrollment target is 156 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT00708175, a Phase 4 study of Bone Metabolism, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 156 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pioglitazone
Study Locations (20)
California
- - Greenbrae
- - Los Banos
- - San Diego
- - Walnut Creek
- - West Hills
Florida
- - Boynton Beach
- - Hialeah
- - Jupiter
Colorado
- - Lakewood
- - Longmont
Georgia
- - Dunwoody
- - Gainesville
Iowa
- - Des Moines
- - Iowa City
Hawaii
- - Honolulu
Idaho
- - Idaho Falls
Illinois
- - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00708175
The ClinicalTrials.gov registry entry for NCT00708175 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bone Metabolism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00708175 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00708175 about?
NCT00708175 is a clinical study titled "Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.". The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.
What is the current status of trial NCT00708175?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 156 participants. The study started on 2008-05. Estimated completion is 2011-02.
What conditions does trial NCT00708175 study?
This clinical trial studies the following conditions: Bone Metabolism.
What interventions are being tested in trial NCT00708175?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00708175?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00708175 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.